In vitro inhibitory effects of Wen-pi-tang-Hab-Wu-ling-san on human cytochrome P450 isoforms

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 4, 2011, Pages 496-503

  Lee, H W ^a,b   Kim, D W ^a,b,c   Phapale, P B ^a,b,c   Lim, M S ^a,b,c   Park, J ^a,b,c   Seo, J J ^a,b,c   Park, K M ^c   Park, Y K ^d   Yoon, Y R ^a,b,c  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Dongguk University   (South Korea)

Author keywords

cytochrome P450; drug herb interactions; herbal medicine; UPLC; Wen pi tang Hab Wu ling san

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; PLANT EXTRACT; UNCLASSIFIED DRUG; WEN PI TANG HAB WU LING SAN EXTRACT;

ANIMAL MODEL; ARTICLE; DRUG INHIBITION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KIDNEY INJURY; KOREAN MEDICINE; LIVER MICROSOME; MEDICINAL PLANT; MOUSE; NONHUMAN; WEN PI TANG HAB WU LING SAN;

CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; HERB-DRUG INTERACTIONS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MICROSOMES, LIVER; REPUBLIC OF KOREA;

EID: 79960090549     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01201.x     Document Type: Article

References (44)

1. Lee SI, Kim HJ, Baek M-C, Park KM, Park Y, Yoon CH, Boo YC, (2007) Wen-pi-tang-Hab-Wu-ling-san, an oriental herbal prescription, attenuates epithelial-mesenchymal transdifferentiation stimulated by TGF-β1 in kidney cells. Phytotherapy Research, 21, 548-553. (Pubitemid 46910231)
2. Nakagawa T, Yokozawa T, Kim YA, Kang KS, Tanaka T, (2005) Activity of wen-pi-tang, and purified constituents of rhei rhizome and glycyrrhizae radix against glucose-mediated protein damage. American Journal of Chinese Medicine, 33, 817-829. (Pubitemid 41319931)
3. Jung HW, Yoon C-H, Kim YH, Boo YC, Park KM, Park Y-K, (2007) Wen-pi-tang-Hab-Wu-ling-san extract inhibits the release of inflammatory mediators from LPS-stimulated mouse macrophages. Journal of Ethnopharmacology, 114, 439-445. (Pubitemid 350026228)
4. Yokozawa T, Rhyu DY, Cho EJ, (2003) Protection by the Chinese prescription Wen-Pi-Tang against renal tubular LLC-PK1 cell damage induced by 3-morpholinosydnonimine. Journal of Pharmacy and Pharmacology, 55, 1405-1412. (Pubitemid 37321384)
5. Seok YM, Kim J, Park MJ, Boo YC, Park Y-K, Park KM, (2008) Wen-pi-tang-Hab-Wu-ling-san attenuates kidney fibrosis induced by ischemia/reperfusion in mice. Phytotherapy Research, 22, 1057-1063.
6. De Smet PAGM, (2002) Herbal remedies. New England Journal of Medicine, 347, 2046-2056. (Pubitemid 35461662)
7. Zhou S, Xue CC, Yu X, Wang G, (2007) Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Current Drug Metabolism, 8, 526-553. (Pubitemid 47209094)
8. Zhou S, Koh H-L, Gao Y, Gong Z, Lee EJD, (2004) Herbal bioactivation: the good, the bad and the ugly. Life Sciences, 74, 935-968. (Pubitemid 37522131)
9. Hellum BH, H Z, Nilse OG, (2007) The induction of CYP1A2, CYP2D6, and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic & Clinical Pharmacology & Toxicology, 100, 23-30. (Pubitemid 46051439)
10. Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD, (2004) Herb-drug interactions: an evidence based approach. Current Medicinal Chemistry, 11, 1513-1525. (Pubitemid 38735793)
11. Zou L, Harkey MR, Henderson GL, (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sciences, 71, 1579-1589. (Pubitemid 34808718)
12. Hall SD, Wang Z, Huang S-M, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC, (2003) The interaction between St John's wort and an oral contraceptive. Clinical Pharmacology and Therapeutics, 74, 525-535. (Pubitemid 37521996)
13. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S, (2005) Herb-drug interactions: a literature review. Drugs, 65, 1239-1282. (Pubitemid 41038418)
14. Wilkinson GR, (2005) Drug metabolism and variability among patients in drug response. New England Journal of Medicine, 352, 2211-2221.
15. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW, (2003) Interactions of herbs with cytochrome P450. Drug Metabolism Reviews, 35, 35-98. (Pubitemid 36249785)
16. Evans WE, Relling MV, (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
17. Ingelman-Sundberg M, (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends in Pharmacological Sciences, 25, 193-200. (Pubitemid 38519910)
18. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y, (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacological Reviews, 50, 387-411. (Pubitemid 28477680)
19. Seok YM, Kim J, Choi KC, Yoon CH, Boo YC, Park Y, Park KM, (2007) Wen-pi-tang-Hab-Wu-ling-san attenuates kidney ischemia/reperfusion injury in mice. A role for antioxidant enzymes and heat-shock proteins. Journal of Ethnopharmacology, 112, 333-340. (Pubitemid 46778960)
20. Tucker GT, Houston JB, Huang SM, (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharmaceutical Research, 18, 1071-1080. (Pubitemid 32900389)
21. Liu KH, Lee YM, Shon JH, Kim MJ, Lee SS, Yoon YR, Cha IJ, Shin JG, (2004) Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica, 34, 429-438. (Pubitemid 38901453)
22. Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA, (1997) In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metabolism and Disposition, 25, 1130-1136. (Pubitemid 27446582)
23. Liu KH, Kim MJ, Jeon BH, Shon JH, Cha IJ, Cho KH, Lee SS, Shin JG, (2006) Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. Journal of Clinical Pharmacy and Therapeutics, 31, 83-91.
24. Bosch ME, Sánchez AJR, Rojas FS, Ojeda CB, (2007) Analytical methodologies for the determination of omeprazole: an overview. Journal of Pharmaceutical and Biomedical Analysis, 44, 831-844.
25. Jia H, Li W, Zhao K, (2006) Determination of omeprazole in rat plasma by high-performance liquid chromatography without solvent extraction. Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 837, 112-115. (Pubitemid 44208756)
26. Ha HR, Rentsch KM, Kneer J, Vonderschmit DJ, (1993) Determination of midazolam and its [alpha]-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography. Therapeutic Drug Monitoring, 15, 338-343. (Pubitemid 23237587)
27. Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, Kuroiwa Y, (1998) Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalyzed by human CYP1A2. British Journal of Clinical Pharmacology, 45, 361-368. (Pubitemid 28138828)
28. Lam YWF, Rodriguez SY, (1993) High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Therapeutic Drug Monitoring, 15, 300-304. (Pubitemid 23237581)
29. Mastey V, Panneton AC, Donati F, Varin F, (1994) Determination of midazolam and two of its metabolites in human plasma by high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Applications, 655, 305-310. (Pubitemid 24169266)
30. Palamanda J, Feng W-W, Lin C-C, Nomeir AA, (2000) Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system. Drug Metabolism and Disposition, 28, 38-43. (Pubitemid 30027510)
31. Peng SX, Barbone AG, Ritchie DM, (2003) High-throughput cytochrome P450 inhibition assays by ultrafast gradient liquid chromatography with tandem mass spectrometry using monolithic columns. Rapid Communications in Mass spectrometry, 17, 509-518. (Pubitemid 36373014)
32. Nelson DR, (2002) Introductory remarks on human CYPs. Drug Metabolism Reviews, 34, 1-5. (Pubitemid 34311083)
33. Rodrigues AD, Surber BW, Yao Y, Wong SL, Roberts EM, (1997) [O-Ethyl 14C] phenacetin O-deethylase activity in human liver microsomes. Drug Metabolism and Disposition, 25, 1097-1100. (Pubitemid 27396499)
34. Tang C, Lin Y, Rodrigues AD, Lin JH, (2002) Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metabolism and Disposition, 30, 648-654. (Pubitemid 34579097)
35. Wang J-S, Wen X, Backman JT, Neuvonen PJ, (2002) Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 302, 43-49. (Pubitemid 34680419)
36. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T, (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. Journal of Pharmacology and Experimental Therapeutics, 266, 52-59. (Pubitemid 23315627)
37. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T, (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3, 197-204. (Pubitemid 23265487)
38. Kerry NL, Somogyi AA, Bochner F, Mikus G, (1994) The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. British Journal of Clinical Pharmacology, 38, 243-248. (Pubitemid 24282745)
39. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ, (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics, 5, 143-150.
40. Lejus C, Fautrel A, Malledant Y, Guillouzo A, (2002) Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochemical Pharmacology, 64, 1151-1156. (Pubitemid 35247823)
41. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D, (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition, 24, 940-947. (Pubitemid 26314544)
42. Wang J-S, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, Kivisto KT, (1999) Midazolam a-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacology & Toxicology (Copenhagen), 85, 157-161. (Pubitemid 29484980)
43. Dierks EA, Stams KR, Lim H-K, Cornelius G, Zhang H, Bal SE, (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450S using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metabolism and Disposition, 29, 23-29. (Pubitemid 32041675)
44. Venkataramanan R, Komoroski B, Strom S, (2006) In vitro and in vivo assessment of herb drug interactions. Life Science, 78, 2105-2115.